(Q40784297)

23 September 2017

title

Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer? (English)

1 reference

23 September 2017

Schröder FH

1

1 reference

23 September 2017

Kranse R

2

1 reference

23 September 2017

Barbet N

3

1 reference

23 September 2017

Hop WC

4

1 reference

23 September 2017

Kandra A

5

1 reference

23 September 2017

Lassus M

6

1 reference

23 September 2017

publication date

1 February 2000

1 reference

23 September 2017

1 reference

23 September 2017

volume

42

1 reference

23 September 2017

issue

2

1 reference

23 September 2017

page(s)

107-115

1 reference

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Planning a longitudinal study. II. Frequency of measurement and study duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0045%2820000201%2942%3A2%3C107%3A%3AAID-PROS4%3E3.0.CO%3B2-E

10.1002/(SICI)1097-0045(20000201)42:2<107::AID-PROS4>3.0.CO;2-E

21 January 2018

Identifiers

DOI

1 reference

23 September 2017

1 reference